Skip to main navigation

Oyster Point Pharma Announces US FDA Approval of Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

This site is intended for US audiences only

Investors & Media
Careers
Contact

Who We Are
Science & Pipeline
Our Focus
Our Therapies

Oyster Point Pharma Announces US FDA Approval of Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

Who We Are
Science & Pipeline
Our Focus
Our Therapies
Investors & Media
Careers
Contact

This site is intended for US audiences only

News Releases

Breadcrumb

Home
Investors
News and events
News Releases

Year

Nov 30, 2021

Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference

PDF Version

Nov 24, 2021

Oyster Point Pharma Announces Expansion of Executive Leadership Team to Support Commercialization of Tyrvaya™ (varenicline solution) Nasal Spray for the Signs and Symptoms of Dry Eye Disease

PDF Version

Nov 15, 2021

Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYAᵀᴹ (varenicline solution) Nasal Spray

PDF Version

Nov 09, 2021

Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021

PDF Version

Nov 04, 2021

Oyster Point Pharma Reports Third Quarter 2021 Financial Results and Recent Business Highlights

PDF Version

Nov 04, 2021

Oyster Point Pharma Announces Patient Savings Program Where Eligible Patients Can Pay as Little as $0 for TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of The Signs and Symptoms of Dry Eye Disease

PDF Version

Nov 03, 2021

Oyster Point Pharma’s TYRVAYA™ (varenicline solution) Nasal Spray is Now Available at U.S. Regional Wholesalers for Distribution to Pharmacies for the Treatment of the Signs and Symptoms of Dry Eye Disease

PDF Version

Nov 02, 2021

Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021

PDF Version

Oct 28, 2021

Oyster Point Pharma to Report Third Quarter 2021 Financial Results on November 4, 2021

PDF Version

Oct 18, 2021

Oyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease

PDF Version

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 30

Shareholder Tool

Print Page button

Email Alerts button

Information Request button

Information Request

Footer Links

Who We Are
Science & Pipeline
Our Focus
Investors & Media
Careers
Contact Us

Legal Links

Privacy Policy
Terms of Use
Cookie Policy

© 2021 Oyster Point Pharma, Inc., TYRVAYA™, and the Oyster Point logo are trademarks of Oyster Point Pharma, Inc.

We use cookies to deliver our online services. Details of the cookies can be found by clicking the 'Cookie settings' link. To agree to our use of cookies click 'Accept.'. Cookie settings ACCEPT

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. The cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We...

Necessary

Necessary

Always Enabled

SAVE & ACCEPT